Linked Life Data

2809200

Source:http://linkedlifedata.com/resource/pubmed/id/2809200

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1989-12-15
pubmed:abstractText
Both IL-3 and IL-4 have multi-CSF activity on early marrow progenitors. We have examined the effect of IL-3 and IL-4 on the differentiation of NK cells from their marrow-derived precursors and have further examined the interactions of these cytokines with IL-2 and IL-1. We tested marrow which had been depleted of mature cells and of E rosette-positive cells (including NK cells) by treatment with soybean lectin and SRBC (SBA-E-BM). The cytolytic activities of the SBA-E-BM samples were tested in 51Cr-release assays after 7 days of liquid culture. K562 targets were used as a measure of NK activity and NK-resistant Daudi targets were used to measure lymphokine-activated killer (LAK) cell activity. Neither NK nor LAK activity was detectable in marrow cultured in medium without cytokines, or in medium containing IL-3, or IL-4 alone. Both of these cytokines were shown to be inhibitory to the IL-2-induced generation of NK and LAK activity from SBA-E-BM at concentrations as low as 1 U/ml. The inhibitory activity of both IL-3 and IL-4 was found to occur early in the marrow cultures, with little or no inhibitory effects seen if added 48 h after IL-2. IL-3 appeared to be specifically inhibitory to NK cell precursors since addition of IL-3 to cultures of PBMC did not inhibit IL-2-induced lytic activities. In contrast, IL-4 was equally inhibitory to the activation of marrow and peripheral blood NK cells by IL-2. Mixing experiments demonstrated that the reduced lytic activity in IL-3 or IL-4 containing marrow cultures were not due to suppression of the NK effectors, nor could marrow cultured in IL-3 or IL-4 serve as targets for IL-2-activated NK cells. Phenotype analysis of the lymphoid cells in marrow cultures containing IL-2 combined with IL-3 or IL-4 revealed fewer cells expressing Leu-11 (CD16), or Leu-19 (CD56) and fewer CD16, CD56 coexpressing cells compared with marrow cultured in medium containing IL-2 alone. The inhibitory activity of IL-4, but not IL-3, could be partially reversed if IL-1 was added to the cultures, suggesting that IL-1 and IL-4 have opposing activities on NK cells responsiveness to IL-2. These interactions between cytokines might be important in the regulation of NK cell differentiation and on the functional activity of mature NK cells.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
143
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3241-9
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:2809200-Bone Marrow, pubmed-meshheading:2809200-Cells, Cultured, pubmed-meshheading:2809200-Culture Media, pubmed-meshheading:2809200-Cytotoxicity, Immunologic, pubmed-meshheading:2809200-Dose-Response Relationship, Immunologic, pubmed-meshheading:2809200-Hematopoietic Stem Cells, pubmed-meshheading:2809200-Humans, pubmed-meshheading:2809200-Interleukin-1, pubmed-meshheading:2809200-Interleukin-2, pubmed-meshheading:2809200-Interleukin-3, pubmed-meshheading:2809200-Interleukin-4, pubmed-meshheading:2809200-Killer Cells, Lymphokine-Activated, pubmed-meshheading:2809200-Killer Cells, Natural, pubmed-meshheading:2809200-Kinetics, pubmed-meshheading:2809200-Lectins, pubmed-meshheading:2809200-Leukocytes, Mononuclear, pubmed-meshheading:2809200-Lymphocyte Activation, pubmed-meshheading:2809200-Phenotype, pubmed-meshheading:2809200-Plant Lectins, pubmed-meshheading:2809200-Rosette Formation, pubmed-meshheading:2809200-Soybean Proteins, pubmed-meshheading:2809200-Suppressor Factors, Immunologic
pubmed:year
1989
pubmed:articleTitle
Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
pubmed:affiliation
Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York 10021.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't